Experimental Animal Models for Influenza/Flu Virus Vaccine Development
Abstract
Objectives: The objective of this review is to explore the different animal models used in the development of Influenza / Flu Virus Vaccine as well as some important guidelines adhered to it.
Methods: Laboratory animal models are widely used in the preclinical evaluation of potential vaccines and antiviral compounds to investigate the safety and efficacy of the vaccine or compound in preventing or moderating infection, disease, or secondary transmission. Animal models must also represent humans in terms of similarity of clinical signs, histopathological changes, virus growth kinetics, or transmission. Common animal models for influenza virus vaccine testing include mice, ferrets, and non-human primates. These models help researchers assess vaccine efficacy, immune response, and potential side effects before advancing to human trials. Animal models play a crucial role in the development and testing of influenza vaccines, as they help researchers examine potential side effects and adverse reactions, evaluate the efficacy of vaccines, study the immune response elicited by vaccines, understand the pathogenesis of influenza virus infection, and predict the potential impact of emerging strains. They also help test various vaccine platforms and delivery methods, and compare the effectiveness of different vaccine formulations in animals to identify promising candidates for further human trials.
Results: We have discussed in detail the various animal models such as Chick embryo model for the development of influenza virus vaccine and mice, ferrets, guinea pig and non-human primates etc. used for the evaluation of safety and therapeutic effectiveness.
Conclusion: As we have discussed various animal models, their merits, demerits etc. for the evaluation of safety and effectiveness of influenza virus vaccine and expect that these will help for the young researchers to carry out their vaccine research using suitable animal models.
Keywords: influenza virus, vaccine development, mouse models, ferret model, guinea pig model, cotton rat model
Keywords:
influenza virus, vaccine development, mouse models, ferret model, guinea pig model, cotton rat modelDOI
https://doi.org/10.22270/jddt.v14i2.6362References
Margine I, Krammer F. Animal models for influenza viruses: Implications for universal vaccine development. Pathogens. MDPI AG; 2014;3: 846-74. https://doi.org/10.3390/pathogens3040845 PMid:25436508 PMCid:PMC4282889
Blumel J, Burger R, Drosten C, Groner A, Gurtler L, Heiden M, et al. Influenza virus. Transfusion Medicine and Hemotherapy. 2009; 36:32-9. https://doi.org/10.1159/000197314 PMid:21048819 PMCid:PMC2928832
Nguyen TQ, Rollon R, Choi YK. Animal models for influenza research: Strengths and weaknesses. Viruses. MDPI AG; 2021;13(6):1011. https://doi.org/10.3390/v13061011 PMid:34071367 PMCid:PMC8228315
Kalil AC, Thomas PG. Influenza virus-related critical illness: Pathophysiology and epidemiology. Critical Care. BioMed Central Ltd.; 2019;23:01-07. https://doi.org/10.1186/s13054-019-2539-x PMid:31324202 PMCid:PMC6642581
Dewangan V, Sahu RK, Satapathy T. Incidence of moxifloxacin serious adverse drug reactions in pneumococcal infections virus infected patients detected by a Pharmacovigilance program by laboratory signals in a Tertiary Hospital in Chhattisgarh (India). Research Journal of Pharmacology and Pharmacodynamics 2022; 14(4): 237-245. https://doi.org/10.52711/2321-5836.2022.00041
Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infections: The contributions of virus and host factors. Current Opinion in Immunology. 2011; 23:481-6. https://doi.org/10.1016/j.coi.2011.07.016 PMid:21840185 PMCid:PMC3163725
Bouvier NM, Lowen AC. Animal models for influenza virus pathogenesis and transmission. Viruses. 2010;2(8):1530-63. https://doi.org/10.3390/v20801530 PMid:21442033 PMCid:PMC3063653
Thangavel RR, Bouvier NM. Animal models for influenza virus pathogenesis, transmission, and immunology. Journal of Immunological Methods. Elsevier; 2014; 410:60-79. https://doi.org/10.1016/j.jim.2014.03.023 PMid:24709389 PMCid:PMC4163064
Dewangan V, Sahu R, Satapathy T, Roy A. The Exploring of Current Development status and the unusual Symptoms of Coronavirus Pandemic (Covid-19) Res. J. Pharmacology and Pharmacodynamics.2020; 12(4):172-176. https://doi.org/10.5958/2321-5836.2020.00031.2
Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and Ecology of Influenza A Viruses. Microbiological Reviews.1992;56(1):152-79. https://doi.org/10.1128/mr.56.1.152-179.1992 PMid:1579108 PMCid:PMC372859
Palese P, Wang TT. H5N1 influenza viruses: Facts, not fear. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:2211-3. https://doi.org/10.1073/pnas.1121297109 PMid:22308474 PMCid:PMC3289294
Dewangan H, Tiwari RK, Sharma V, Shukla SS, Satapathy T, Pandey R. Past and Future of in-vitro and in-vivo Animal Models for Diabetes: A Review. Indian Journal of Pharmaceutical Education and Research. 2017;51(4S):S522-S30. https://doi.org/10.5530/ijper.51.4s.79
Dhalendra G, Satapathy T, Roy A. Animal Models for Inflammation: A Review. Asian Journal of Pharmaceutical Research.2013;3(4):207-212.
Wan-Zhen Zhu, Yi-Chi Wen, Shu-Yi Lin, Ting-Chih Chen, and Hui-Wen Chen. Anti-Influenza Protective Efficacy of a H6 Virus-Like Particle in Chickens. MDPI, 2020;8(3):465. https://doi.org/10.3390/vaccines8030465 PMid:32825685 PMCid:PMC7565593
Davis T, Bialy D, Leng J, La Ragione R, Shelton H, Chrzastek K. Alteration of the Chicken Upper Respiratory Microbiota, Following H9N2 Avian Influenza Virus Infection. Pathogens. 2023;12(9):1168. https://doi.org/10.3390/pathogens12091168 PMid:37764976 PMCid:PMC10534358
Fonseca dos Reis E, Viney M, Masuda N. Network analysis of the immune state of mice. Sci Rep. 2021;11(1). https://doi.org/10.1038/s41598-021-83139-7 PMid:33619299 PMCid:PMC7900184
Wasik BR, Voorhees IEH, Barnard KN, Alford-Lawrence BK, Weichert WS, Hood G, et al. Influenza Viruses in Mice: Deep Sequencing Analysis of Serial Passage and Effects of Sialic Acid Structural Variation.2019;93(23). https://doi.org/10.1128/JVI.01039-19 PMid:31511393 PMCid:PMC6854484
Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, et al. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Molecular Therapy. 2020;28(7):1569-84. https://doi.org/10.1016/j.ymthe.2020.04.018 PMid:32359470 PMCid:PMC7335735
Barackman JD, Ott G, O'hagan DT. Intranasal Immunization of Mice with Influenza Vaccine in Combination with the Adjuvant LT-R72 Induces Potent Mucosal and Serum Immunity Which Is Stronger than That with Traditional Intramuscular Immunization. Infection and Immunity. 1999; 67(8): 4276-4279. https://doi.org/10.1128/IAI.67.8.4276-4279.1999 PMid:10417205 PMCid:PMC96738
Enkirch T, von Messling V. Ferret models of viral pathogenesis. Virology.2015;479-480:259-70. https://doi.org/10.1016/j.virol.2015.03.017 PMid:25816764 PMCid:PMC7111696
Oh DY, Hurt AC. Using the ferret as an animal model for investigating influenza antiviral effectiveness. Frontiers in Microbiology. Frontiers Media S.A.; 2016;7:01-12. https://doi.org/10.3389/fmicb.2016.00080
Belser JA, Katz JM, Tumpey TM. The ferret as a model organism to study influenza A virus infection. DMM Disease Models and Mechanisms. 2011; 4:575-9. https://doi.org/10.1242/dmm.007823 Mid:21810904 PMCid:PMC3180220
Belser JA, Eckert AM, Huynh T, Gary JM, Ritter JM, Tumpey TM, et al. A Guide for the Use of the Ferret Model for Influenza Virus Infection. American Journal of Pathology. Elsevier Inc.; 2020; 190:11-24. https://doi.org/10.1016/j.ajpath.2019.09.017 PMid:31654637 PMCid:PMC8264465
Lowen AC, Bouvier NM, Steel J. Transmission in the guinea pig model. Curr Top Microbiol Immunol. 2014;385:157-83. https://doi.org/10.1007/82_2014_390 PMid:25001209 PMCid:PMC7121145
Lowen AC, Mubareka S, Tumpey TM, García-Sastre A, Palese P. The guinea pig as a transmission model for human influenza viruses [Internet]. 2006; 103:9988-9992. Available from: www.pnas.orgcgidoi10.1073pnas.0604157103. https://doi.org/10.1073/pnas.0604157103 PMid:16785447 PMCid:PMC1502566
Mubareka S, Lowen AC, Steel J, Coates AL, García-Sastre A, Palese P. Transmission of influenza virus via aerosols and fomites in the guinea pig model. Journal of Infectious Diseases. 2009;199(6):858-65.https://doi.org/10.1086/597073 PMid:19434931 PMCid:PMC4180291
Bushnell RV, Tobin JK, Long J, Schultz-Cherry S, Chaudhuri AR, Nara PL, et al. Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein [Internet]. 2010. https://doi.org/10.1186/1743-422X-7-200
PMid:20735849 PMCid:PMC2939558 28. Boukhvalova MS, Prince GA, Blanco JCG. The cotton rat model of respiratory viral infections. Biologicals. 2009;37(3):152-9. https://doi.org/10.1016/j.biologicals.2009.02.017 PMid:19394861 PMCid:PMC2882635
Eichelberger MC. The cotton rat as a model to study influenza pathogenesis and immunity. Viral Immunology. 2007; 20:243-9. https://doi.org/10.1089/vim.2007.0017 PMid:17603841
Green MG, Huey D, Niewiesk S. The cotton rat (Sigmodon hispidus) as an animal model for respiratory tract infections with human pathogens. Lab Anim (NY). 2013;42(5):170-6. https://doi.org/10.1038/laban.188 PMid:23604159
Ottolini MG, Blanco JCG, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, et al. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. Journal of General Virology. 2005;86(10):2823-30. https://doi.org/10.1099/vir.0.81145-0 PMid:16186238
Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, Sakai-Tagawa Y, Noda T, Hasegawa H, et al. Syrian Hamster as an Animal Model for the Study of Human Influenza Virus Infection. J Virol. 2018;92(4):10-128. https://doi.org/10.1128/JVI.01693-17 PMid:29212926 PMCid:PMC5790951
Ali MJ, Teh CZ, Jennings R, Potter CW. Transmissibility of influenza viruses in hamsters. Archives of virology. 1982;72:187-97. https://doi.org/10.1007/BF01348964 PMid:7115086
Lisa A Miller, Christopher M Royer, Kent E Pinkerton, Edward S Schelegle Nonhuman Primate Models of Respiratory Disease: Past, Present, and Future. ILAR Journal. 2017;58(2): 269-280. https://doi.org/10.1093/ilar/ilx030 PMid:29216343 PMCid:PMC5886323
Tarantal AF, Noctor SC, Hartigan-O'Connor DJ. Nonhuman Primates in Translational Research Annu Rev Anim Biosci. 2022;10:441-468. https://doi.org/10.1146/annurev-animal-021419-083813 PMid:35167321 PMCid:PMC9339229
Zhang K, Xu W, Zhang Z, Wang T, Sang X, Cheng K, et al. Experimental infection of non-human primates with avian influenza virus (H9N2). Arch Virol. 2013;158(10):2127-34. https://doi.org/10.1007/s00705-013-1721-8 PMid:23665767
Moncla LH, Ross TM, Dinis JM, Weinfurter JT, Mortimer TD, Schultz-Darken N, et al. A novel nonhuman primate model for influenza transmission. PLoS One. 2013;8(11):01-10. https://doi.org/10.1371/journal.pone.0078750 PMid:24244352 PMCid:PMC3828296
Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, et al. The marmoset as an animal model of influenza: Infection with A(H1N1)pdm09 and highly pathogenic a(H5N1) viruses via the conventional or tracheal spray route. Front Microbiol. 2018;9:01-10. https://doi.org/10.3389/fmicb.2018.00844 PMid:29867791 PMCid:PMC5954801
Roubidoux EK, Schultz-Cherry S. Animal models utilized for the development of influenza virus vaccines. Vaccines. 2021;9(7):787. https://doi.org/10.3390/vaccines9070787 PMid:34358203 PMCid:PMC8310120
Rajao DS, Vincent AL. Swine as a model for influenza virus infection and immunity. ILAR J. 2015 May 19;56(1):44-52. https://doi.org/10.1093/ilar/ilv002 PMid:25991697
Opriessnig T, Gauger PC, Filippsen Favaro P, Rawal G, Magstadt DR, Digard P, et al. An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.Vaccine. 2023: 01-09. https://doi.org/10.1016/j.vaccine.2023.12.012 PMid:38087714
Published



How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).